Nutriband Inc. (NASDAQ: NTRB), a developer of innovative transdermal pharmaceutical products, has been granted a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark “AVERSA.” This notice indicates that the USPTO is expected to officially register the trademark following the completion of administrative procedures.
Nutriband’s proprietary AVERSA™ technology is designed to integrate aversive agents into transdermal patches, creating an unpleasant experience that deters substance abuse. This technology is particularly critical for drugs with a high potential for abuse, such as fentanyl. The company’s flagship product under development, AVERSA Fentanyl, leverages this technology to enhance safety and reduce the risk of abuse.
To advance AVERSA Fentanyl, Nutriband is collaborating with Kindeva Drug Delivery. The partnership began with a feasibility agreement and has evolved into a commercial-development and clinical-supply agreement. This collaboration aims to scale up the commercial manufacturing process for AVERSA Fentanyl, targeting a planned human-abuse potential clinical study. This study is a key component for the New Drug Application (NDA) that Nutriband plans to submit to the U.S. Food and Drug Administration (FDA).
According to the company, “AVERSA aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles.” The technology’s significance is underscored by its robust intellectual property portfolio, which includes patents granted in the United States and several other countries, such as Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
The AVERSA™ trademark is a cornerstone of Nutriband’s platform technology, which is designed to prevent the abuse, diversion, misuse, and accidental exposure of drugs with high abuse potential. The trademark’s approval is a crucial step in the company’s mission to develop safer pharmaceutical products and expand its market presence.
For more detailed information about Nutriband Inc. and its innovative technologies, visit the company’s website at https://www.nutriband.com.
Source IBN
